// App-Quantinova.ai

: DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION

Researchers

Presenter

  • Kaori Uchino

Principal Investigators

  • Tomohiro Horio

  • Motonori Mizutani

  • Ayano Nakamura

  • Souichi Takasugi

  • Ichiro Hanamura

  • Lam Vu

  • Yoshihisa Kodera

  • J. Luis Espinoza

  • Makoto Onizuka

  • Koichi Kashiwase

  • Yasuo Morishima

  • Takahiro Fukuda

  • Noriko Doki

  • Koichi Miyamura

  • Takehiko Mori

  • Eriko Morishita

  • Shinji Nakao

  • Akiyoshi Takami

Medical Centers

  • Aichi Medical University, Nagakute, Japan.

  • Kinki University, Osaka, Japan

  • Tokai University, Isehara, Japan.

  • Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

  • Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

  • Teikyo University, Tokyo, Japan

  • Kanazawa University, Kanazawa, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Major Histocompatibility Complex, Class I, A

  • Major Histocompatibility Complex, Class I, B

  • Major Histocompatibility Complex, Class II, DQ Beta 1

  • Major histocompatibility complex, class II, DR beta 1

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved